Search
Vipadenant
go.drugbank.com/drugs/DB06625InvestigationalCategories: Purinergic P1 Receptor AntagonistsNamodenoson
go.drugbank.com/drugs/DB12885InvestigationalNamodenoson has been used in trials studying the treatment of Chronic Hepatitis C and Hepatocellular Carcinoma.
Categories: Purinergic P1 Receptor AgonistsDPCPX
go.drugbank.com/drugs/DB12946InvestigationalCPX has been used in trials studying the treatment of Cystic Fibrosis.
Categories: Purinergic P1 Receptor AntagonistsBinodenoson
go.drugbank.com/drugs/DB04853InvestigationalBinodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A2A receptor. This specificity allows Binodenoson to deliver - in a single injection - a more effective d...
Categories: Purinergic P1 Receptor AgonistsIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigationalIstradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTecadenoson
go.drugbank.com/drugs/DB04954InvestigationalTecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.
Categories: Purinergic P1 Receptor AgonistsClopidogrel
go.drugbank.com/drugs/DB00758ApprovedInvestigationalClopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: CLOPIDOGREL E ACIDO ACETILSALICILICO BILLEVAminophylline
go.drugbank.com/drugs/DB01223ApprovedInvestigationalAminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: AMINOFILLINA BIL